(Wiley-Blackwell) The Food and Drug Administration received reports of malignancies in children using tumor necrosis factor a (TNF) blockers, raising concerns of an associated risk and prompting an investigation. Researchers from the FDA set out to identify all reports of malignancy in children using infliximab, etanercept, and adalimumab and their report is published in the August issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.
Read »Navigation
User login
Visit the BiotechMashup Blog
Best upcoming scoops - Chemistry
- Brain capacity limits exponential online data growth
- Murine GRPR and Stathmin Control in Opposite Directions both Cued Fear Extinction and Neural Activities of the Amygdala and Pref
- Responsiveness to 6-n-Propylthiouracil (PROP) Is Associated with Salivary Levels of Two Specific Basic Proline-Rich Proteins in
- Environmentally Realistic Exposure to the Herbicide Atrazine Alters Some Sexually Selected Traits in Male Guppies
- Sleep Disorders and Demand for Medical Services: Evidence from a Population-Based Longitudinal Study